Skip to main content
Erschienen in: Surgical Endoscopy 11/2010

01.11.2010 | Letter

High-quality clinical practice: laparoscopic rectal cancer resection

verfasst von: Georgios Baltogiannis, Christos Katsios

Erschienen in: Surgical Endoscopy | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Excerpt

Modern current and emerging technology and scientific expertise drive the outcomes of patients with potentially curable, nonmetastatic solid cancer. Despite advances in multimodal therapeutics, current failure rates in both locoregional and distant systemic treatment remain alarmingly high resulting in the death of most patients with advanced colorectal cancer. …
Literatur
1.
Zurück zum Zitat Cheung YM, Lange MM, Buunen M, Lange JF (2009) Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc 23:2796–2801CrossRef Cheung YM, Lange MM, Buunen M, Lange JF (2009) Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc 23:2796–2801CrossRef
2.
Zurück zum Zitat Poon JT, Law WL (2009) Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol 16(11):3038–3047CrossRefPubMed Poon JT, Law WL (2009) Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol 16(11):3038–3047CrossRefPubMed
3.
Zurück zum Zitat Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696CrossRefPubMed Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696CrossRefPubMed
4.
Zurück zum Zitat Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefPubMed Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefPubMed
5.
Zurück zum Zitat Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMed Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMed
6.
Zurück zum Zitat Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMed Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMed
7.
Zurück zum Zitat Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef
8.
Zurück zum Zitat Briasoulis E, Fatouros M, Roukos D (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695CrossRefPubMed Briasoulis E, Fatouros M, Roukos D (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695CrossRefPubMed
9.
Zurück zum Zitat Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMed Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMed
10.
Zurück zum Zitat Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMed Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMed
11.
Zurück zum Zitat Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMed Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMed
12.
Zurück zum Zitat Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMed Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMed
13.
Zurück zum Zitat Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125CrossRefPubMed Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125CrossRefPubMed
14.
Zurück zum Zitat Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMed Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMed
15.
Zurück zum Zitat Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMed Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMed
16.
Zurück zum Zitat Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715CrossRefPubMed Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715CrossRefPubMed
17.
18.
Zurück zum Zitat Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMed Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMed
19.
Zurück zum Zitat Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMed Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMed
20.
Zurück zum Zitat Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMed Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMed
21.
Zurück zum Zitat Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMed Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMed
22.
Zurück zum Zitat Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMed Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMed
23.
Zurück zum Zitat Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author’s reply 1363)CrossRefPubMed Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author’s reply 1363)CrossRefPubMed
24.
Zurück zum Zitat Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMed Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMed
25.
Zurück zum Zitat Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMed Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMed
26.
Zurück zum Zitat Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMed Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMed
27.
Zurück zum Zitat Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMed Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMed
28.
Zurück zum Zitat Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype–phenotype based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype–phenotype based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed
29.
Zurück zum Zitat Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMed Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMed
30.
Zurück zum Zitat Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMed Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMed
31.
Zurück zum Zitat Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197; author reply 198CrossRefPubMed Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197; author reply 198CrossRefPubMed
32.
Zurück zum Zitat Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590CrossRefPubMed Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590CrossRefPubMed
33.
Zurück zum Zitat Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMed Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMed
34.
Zurück zum Zitat Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMed Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMed
Metadaten
Titel
High-quality clinical practice: laparoscopic rectal cancer resection
verfasst von
Georgios Baltogiannis
Christos Katsios
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Surgical Endoscopy / Ausgabe 11/2010
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-010-1019-9

Weitere Artikel der Ausgabe 11/2010

Surgical Endoscopy 11/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.